{"id":61091,"date":"2023-06-14T20:21:22","date_gmt":"2023-06-14T18:21:22","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-annonce-lacceptation-par-la-fda-de-la-demande-dindication-supplementaire-pour-onivyde-en-premiere-ligne-dun-adenocarcinome-canalaire-pancreatique-metastatique-2688428\/"},"modified":"2024-07-25T08:40:45","modified_gmt":"2024-07-25T06:40:45","slug":"ipsen-annonce-lacceptation-par-la-fda-de-la-demande-dindication-supplementaire-pour-onivyde-en-premiere-ligne-dun-adenocarcinome-canalaire-pancreatique-metastatique-2688428","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-annonce-lacceptation-par-la-fda-de-la-demande-dindication-supplementaire-pour-onivyde-en-premiere-ligne-dun-adenocarcinome-canalaire-pancreatique-metastatique-2688428\/","title":{"rendered":"Ipsen annonce l’acceptation par la FDA de la demande d’indication suppl\u00e9mentaire pour Onivyde en premi\u00e8re ligne d’un\u00a0ad\u00e9nocarcinome canalaire pancr\u00e9atique m\u00e9tastatique"},"content":{"rendered":"